BACKGROUND: The objective of this retrospective study was to investigate the efficacy and tolerability of single-agent docetaxel in patients with platinum-refractory squamous cell carcinoma of the head and neck (SCCHN). METHODS: Platinum-refractory disease was defined as cancer with documented tumor progression during platinum-based treatment or recurrence within 6 months after platinum-based chemoradiotherapy. Patients fulfilling the following criteria were enrolled: histologically confirmed SCCHN, excluding nasopharyngeal cancer; measurable metastatic lesions as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST); and platinum-refractory disease. Docetaxel (60 mg/m2) was administered every 3-4 weeks and continued unless there was evidence of disease progression or unacceptable toxicity. RESULTS: Twenty patients were recruited. Overall response rate was 10% (2/20) and tumor control rate was 25% (5/20). Median progression-free and median overall survival times were 1.7 and 4.6 months, respectively. The most common hematological toxicities were leucopenia (grade 4: 35%) and neutropenia (grade 4: 30%). Grade 3 febrile neutropenia and grade 3 mucositis (functional/symptomatic) each occurred in two patients (10%). One fatal bleeding occurred during this treatment, however, the relation between this event and docetaxel was unlikely. Median inpatient period during treatment was 5.4 days (range, 0-50 days). CONCLUSION: A single-agent docetaxel regimen appeared to offer an acceptable clinical profile in patients with platinum-refractory SCCHN.
BACKGROUND: The objective of this retrospective study was to investigate the efficacy and tolerability of single-agent docetaxel in patients with platinum-refractory squamous cell carcinoma of the head and neck (SCCHN). METHODS:Platinum-refractory disease was defined as cancer with documented tumor progression during platinum-based treatment or recurrence within 6 months after platinum-based chemoradiotherapy. Patients fulfilling the following criteria were enrolled: histologically confirmed SCCHN, excluding nasopharyngeal cancer; measurable metastatic lesions as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST); and platinum-refractory disease. Docetaxel (60 mg/m2) was administered every 3-4 weeks and continued unless there was evidence of disease progression or unacceptable toxicity. RESULTS: Twenty patients were recruited. Overall response rate was 10% (2/20) and tumor control rate was 25% (5/20). Median progression-free and median overall survival times were 1.7 and 4.6 months, respectively. The most common hematological toxicities were leucopenia (grade 4: 35%) and neutropenia (grade 4: 30%). Grade 3 febrile neutropenia and grade 3 mucositis (functional/symptomatic) each occurred in two patients (10%). One fatal bleeding occurred during this treatment, however, the relation between this event and docetaxel was unlikely. Median inpatient period during treatment was 5.4 days (range, 0-50 days). CONCLUSION: A single-agent docetaxel regimen appeared to offer an acceptable clinical profile in patients with platinum-refractory SCCHN.
Authors: Dan P Zandberg; Sandra Rollins; Olga Goloubeva; Robert E Morales; Ming Tan; Rodney Taylor; Jeffrey S Wolf; Lisa M Schumaker; Kevin J Cullen; Ann Zimrin; Robert Ord; Joshua E Lubek; Mohan Suntharalingam; John C Papadimitriou; Dean Mann; Scott E Strome; Martin J Edelman Journal: Cancer Immunol Immunother Date: 2014-12-24 Impact factor: 6.968
Authors: Maura L Gillison; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin J Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara Carmen Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; Li Li; Robert L Ferris Journal: Oncologist Date: 2018-06-04
Authors: Lillian L Siu; Caroline Even; Ricard Mesía; Eva Remenar; Amaury Daste; Jean-Pierre Delord; Jürgen Krauss; Nabil F Saba; Lisle Nabell; Neal E Ready; Irene Braña; Nuria Kotecki; Dan P Zandberg; Jill Gilbert; Hisham Mehanna; Marcelo Bonomi; Anthony Jarkowski; Giovanni Melillo; Jon M Armstrong; Sophie Wildsmith; Jérôme Fayette Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Sara I Pai; Ezra E W Cohen; Derrick Lin; George Fountzilas; Edward S Kim; Holger Mehlhorn; Neus Baste; Daniel Clayburgh; Loren Lipworth; Carlo Resteghini; Nawar Shara; Takashi Fujii; Jun Zhang; Michael Stokes; Huifen Wang; Philip Twumasi-Ankrah; Sophie Wildsmith; Asud Khaliq; Giovanni Melillo; Norah Shire Journal: J Transl Med Date: 2019-12-26 Impact factor: 5.531